In January 2024, your options for telehealth GLP-1 prescribing were limited and expensive. In June 2026, the pricing landscape has fractured into a sprawl of models ranging from $50/month Medicare copays to $500+ premium concierge programs. The price war is real, and the beneficiary is you — but only if you understand what you're actually comparing.
Because a "$99/month" headline price and a "$299/month" all-inclusive program may cost the same over six months once you factor in enrollment fees, lab costs, shipping, dose escalation charges, and the hidden cost of inadequate monitoring.
The 2026 Pricing Landscape
Here's what GLP-1 treatment actually costs across the major access pathways, verified as of spring 2026:
Medicare (starting July 2026)
The Medicare GLP-1 Bridge caps copays at $50/month for Wegovy, oral Wegovy, and Zepbound. Anti-obesity medications are exempt from the Part D deductible. This is the lowest legitimate cost for brand-name GLP-1 medications anywhere — but only available to Medicare Part D beneficiaries meeting BMI criteria.
Branded medications through telehealth
Post-settlement, Hims offers injectable Wegovy at $299/month, oral Wegovy at $249/month, and Zepbound at $399/month. With commercial insurance, eligible patients may pay $0-25/month. Other platforms offer similar pricing for branded products, with variation in what's included beyond the medication itself.
Compounded medications (while still available)
Compounded semaglutide through telehealth platforms ranges from roughly $99-199/month, depending on the platform, dose, and what's included. This segment faces regulatory headwinds — the 503B Bulks List proposal could significantly reduce availability if finalized.
Traditional in-person care
An initial endocrinologist consultation runs $200-400 without insurance. Follow-up visits cost $100-250 each. Add the medication cost and lab fees, and total out-of-pocket for uninsured patients can exceed $800-1,000/month.
What's Actually Included: The True Cost Comparison
The monthly price you see on a telehealth platform's landing page is rarely the complete cost. When comparing options, map out these components:
- Medication: Is the monthly price for the medication itself, or is it a platform/consultation fee with medication billed separately?
- Enrollment/setup fee: Many platforms charge $50-150 upfront for initial evaluation, which doesn't appear in the "per month" advertising
- Lab work: Is baseline and ongoing lab monitoring included? If not, add $100-300 per panel done independently
- Dose escalation: Does the price stay flat as your dose increases, or does cost scale with milligrams? A low introductory price at 0.25mg may double or triple at maintenance doses
- Shipping: Is cold-chain shipping included? Some platforms charge $15-30 per shipment for temperature-controlled delivery
- Follow-up visits: Are clinician consultations included, or billed per visit?
- Coaching/support: Some platforms bundle nutrition coaching, behavioral support, or AI companions. Others charge extra
The Best Value by Patient Profile
Medicare beneficiaries: The $50/month Bridge program is the clear winner starting July 2026. No telehealth platform can compete with Medicare pricing for branded medications.
Commercially insured patients: Check your formulary first. If Wegovy or Zepbound is covered, your copay through any in-network prescriber — including telehealth platforms that accept insurance — may be as low as $25/month with manufacturer savings cards.
Cash-pay patients wanting branded meds: Compare platforms offering Wegovy and Zepbound at standard telehealth pricing. Factor in what's included (labs, follow-up, coaching) rather than just the medication price.
Cash-pay patients prioritizing lowest cost: Compounded options remain the cheapest per-month option where available, but weigh the regulatory uncertainty. Starting a compounded regimen that may be disrupted within 12 months has its own costs — including the difficulty of transitioning mid-treatment.